News

• Interim Report First Quarter 2024, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

  17 May 2024

• Kancera provides operational update regarding the KANDOVA study and reports increased patient recruitment

  16 May 2024

• Kancera appoints new Chief Scientific Officer and extends management team

  8 May 2024

• Kancera meets the primary objectives of the KAND145 clinical phase I study

  3 May 2024

• Kancera announces the outcome of the company’s rights issue

  20 March 2024

• Kancera publishes prospectus in connection with the company’s rights issue

  1 March 2024

• Kancera resolves on a rights issue of approximately SEK 121.9 million

  23 February 2024

• Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study

  23 February 2024

• Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

  23 February 2024

• Kancera presents the statistical analysis of top line data from the FRACTAL study

  6 February 2024